Calcineurin inhibitor

DRUG7 trials

Conditions

Acute-graft-versus-host DiseaseDelayed Graft FunctionHematologic MalignanciesImmunosuppressionKidney TransplantLiver TransplantationRenal FailureRenal Transplant

Phase 1

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

TerminatedNCT03320642

Incyte CorporationHematologic Malignancies

Start: 2018-02-27End: 2022-02-17Updated: 2025-10-21

Phase 2

Effect of Rapamycin on Tolerance-related Biomarkers on Stable Liver Transplant Recipients

NCT01034345

Hospital Clinic of BarcelonaLiver Transplantation

Start: 2009-11-30End: 2011-11-30Target: 52Updated: 2009-12-17

Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function

NCT01837043

Nair, Vinay, D.O.Delayed Graft Function, Kidney Transplant

Start: 2013-06-30End: 2017-06-30Target: 90Updated: 2017-01-30

Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease

NCT02392780

moshe yeshurunAcute-graft-versus-host Disease

Start: 2015-04-30Target: 10Updated: 2015-03-19

Phase 4

Pilot Study for HLA Identical Living Donor Renal Transplant Recipients

CompletedNCT00352092

University of CincinnatiRenal Transplant

Start: 2002-06-30End: 2007-12-31Updated: 2014-11-13

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

NCT01455649

Deise de Boni Monteiro de CarvalhoImmunosuppression, Kidney Transplant

Start: 2011-11-30End: 2013-11-30Target: 30Updated: 2011-10-20

Unknown Phase

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

CompletedNCT01936519

Milton S. Hershey Medical CenterImmunosuppression, Renal Failure

Start: 2013-12-16End: 2019-07-31Updated: 2021-01-29

Related Papers

A Single-Arm, Open-Label Phase 1 Study of Itacitinib (ITA) with Calcineurin Inhibitor (CNI)-Based Interventions for Prophylaxis of Graft-Versus-Host Disease (GVHD; GRAVITAS-119)

Blood2020-11-046 citations

Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD

Blood2018-11-295 citations